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 Cross-enhancement between serotypes a key factor in dengue epidemiology.
 Reappraisal of data suggests cross-enhancement only affects small number of cases.
 Conventional model framework for cross-enhancement revised.
 If enhancement rare, high intensity required to generate multi-annual oscillations.
 Oscillations generated by other drivers modiﬁed by enhancement even if rare.
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a b s t r a c t
Four distinct serotypes of dengue virus co-circulate in many parts of the world. Antibodies to one
serotype prevent infection with the homologous serotype, but may enhance infections with heterologous
serotypes. Enhanced secondary infections have been implicated in the majority of severe cases, termed
dengue hemorrhagic fever. Conventionally, mathematical models assume that all heterologous secondary
infections are subject to enhanced susceptibility or transmissibility. However, empirical data show that
only a minority of secondary infections lead to severe disease, which suggests that only a minority of
secondary infections are subject to enhancement. We present a new modelling framework in which the
population susceptible to secondary infection is split into a group prone to enhanced infection and a
group with some degree of cross-protection. We use this framework to re-evaluate the role of enhanced
infections in several well known dengue models that exhibit multi-annual epidemiological oscillations.
We show that enhancement is unlikely to be driving such oscillations but may be modifying the effects of
other drivers.
& 2014 The Authors. Published by Elsevier Ltd.
1. Introduction
Dengue is a mosquito-borne virus that infects people through-
out tropical and subtropical regions. It causes dengue fever and a
more severe form, dengue hemorrhagic fever (DHF). It is estimated
that over 2.5 billion people are at risk (World Health Organization,
2012) and that there are 390 million dengue infections per year
(Bhatt et al., 2013). There are four distinct serotypes of dengue,
DENV-1, 2, 3, 4. In hyper-endemic regions the prevalence of each
serotype is oscillatory with an 8–10 year cycle (Nisalak et al., 2003;
Recker et al., 2009). The epidemiological dynamics of the four
serotypes are interwoven by immune cross-reaction. Infection
with any serotype results in long-term homologous immunity
and probably a short period of heterologous immunity (Sabin,
1952; Reich et al., 2013). As this heterologous immunity wanes,
antibody-dependent enhancement (ADE) may occur when non-
neutralising antibodies bind to infecting viruses and facilitate cell
entry. The intracellular antiviral response may also be compro-
mised. Consequently ADE accelerates viral production, potentially
leading to higher viremia and more severe disease. See Guzman
and Vazquez (2010) for a review of the ADE mechanism in dengue.
Heterologous secondary infections are implicated in the majority
of dengue hemorrhagic fever (DHF) cases (Gubler and Kuno, 2004).
The standard framework for incorporating ADE into epidemio-
logical models assumes that all individuals that experience a
primary infection then become prone to an enhanced secondary
infection. This enhancement may act by increasing susceptibility
to infection (due to the facilitation of viral entry) and/or increasing
transmission once infection has occurred and/or increasing the
mortality associated with infection (both due to higher viremia).
In the standard modelling framework, enhanced secondary infec-
tions can drive compelling epidemiological dynamics. The impact
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is similar whether enhancement acts through susceptibility or
transmission (Ferguson and Andreasen, 2002; Adams and Boots,
2006). Pioneering mathematical modelling studies showed that in
an unforced two serotype system a relatively small degree of
transmissibility enhancement in secondary infections can result
in periodic or chaotic dynamics with recurrent epidemics each
spanning several years (Ferguson et al., 1999a). It was conse-
quently suggested that ADE may be driving similar underlying
multi-annual epidemiological oscillations observed in dengue
prevalence data. Many studies have explored the phenomenon of
these ‘enhancement-induced’ oscillations (Aguiar et al., 2011),
documenting fascinating dynamics for a range of epidemiological
conditions (Ferguson and Andreasen, 2002; Schwartz et al., 2005;
Adams and Boots, 2006; Billings et al., 2007; Bianco et al., 2009;
Recker et al., 2009; Wikramaratna et al., 2010). Other research has
used similar frameworks to model enhancement but investigated
alternatives to ADE that may be driving epidemiological oscilla-
tions. Stochastic seasonal variation in transmission can sustain
long period oscillations in prevalence, with immune cross-reaction
between serotypes determining the phase relationship between
the time series of their prevalences (Adams et al., 2006). Complete
but temporary heterologous cross-protection can lead to ‘immu-
nity-induced’ oscillatory dynamics in systems where secondary
infections are enhanced or neutral (Wearing and Rohani, 2006), or
even have reduced transmissibility if severe disease associated
with enhanced infection results in rapid hospitalisation (Aguiar
et al., 2008, 2011).
These conventional frameworks assume that all secondary
infections are enhanced. However, in an outbreak of DENV-2 in
Cuba in 1997 only 2–4% of individuals with a secondary infection
had DHF. Genetic predisposition was implicated as a risk factor
(Guzmán et al., 2002; Guzmán and Kouri, 2002). A cohort study of
children in Thailand from 2006 to 2009 found that 96% of DHF
cases had secondary infections, but only 13% of secondary infec-
tions were DHF cases (Sabchareon et al., 2012). A sample of 1009
children in Thailand in 1980 found multitypic seroconversion in
80% of 10–11 year olds (Sangkawibha et al., 1984; Ferguson et al.,
1999b); it is unlikely that such a large proportion also experienced
DHF. Antibody dependent enhancement may occur without lead-
ing to DHF. However, given that accelerated viral replication
underlies the enhancement of susceptibility, transmission and
disease severity, the prevalence of DHF is likely to be a reasonable
estimate for the prevalence of ADE.
These empirical observations lead us to propose a new frame-
work for modelling antibody-dependent enhancement of dengue.
In this framework, the population susceptible to secondary infec-
tions is split into a group prone to enhancement, and a group that
is not prone to enhancement and may have some degree of
protection with respect to secondary infection. We introduce this
framework as a generalisation of the conventional two serotype
model (Ferguson et al., 1999a). With reference to the conventional
model we explore how ADE prevalence and ADE intensity combine
to determine the absence or occurrence of oscillatory dynamics.
We then investigate how the new framework for ADE affects the
behaviour of long period oscillations in a model with stochastic
seasonality (Adams et al., 2006) and a model with temporary
heterologous cross-immunity (Wearing and Rohani, 2006; Aguiar
et al., 2011). It is not our purpose to compare these models with
one another in terms of their capacity to replicate the epidemio-
logical dynamics of dengue. Rather, we have chosen these models
as representative examples of the main approaches to modelling
epidemiological oscillations induced by immune cross-reaction,
and our purpose is to assess the impact of reﬁning the model
framework for cross-enhancement in each of these contexts.
Mathematical modelling is a key part of modern epidemic
control analysis. The core of any dengue model is likely to be
similar to one of the frameworks we consider here. These models
may be used to assess how key properties of the epidemiological
dynamics, for instance prevalence or periodicity, are affected by
intervention or contextual modiﬁcation, for instance vaccines,
vaccine administration programmes, climate changes or the emer-
gence of new serotypes. Enhanced infections are a key component
of dengue epidemiology and so need to be modelled correctly.
Here we argue that this may require some modiﬁcation of the
conventional framework for modelling enhancement. We focus on
the role of enhancement in long period epidemic cycles. We show
that models with the same ‘average’ cross-reaction in the popula-
tion behave similarly. But breaking down the components of this
average in our modiﬁed framework shows that enhancement is
unlikely to be driving these cycles but is likely to be inﬂuencing
the effects of other drivers.
2. Model 1: Two serotype SIR model with partial cross-
enhancement
We now introduce our new framework for modelling cross-
enhancement by modifying the conventional two-serotype SIR
model with enhancement of transmission (Ferguson et al., 1999a;
Adams and Boots, 2006). This model does not permit co-infection
and so can be written as ﬁve intersecting compartments or, as
here, eight disjoint compartments (Fig. 1a) corresponding to:
susceptible to both serotypes (S0), primary infected with serotype
i (Ii), susceptible to secondary infection with serotype i (Si),
secondary infected with serotype i (Ij;i), immune to both serotypes
(R). Natural mortality occurs at rate μ in all compartments.
Individuals susceptible to both serotypes are born at rate μN to
maintain a constant population size N. The vector population is
not explicitly modelled. The immune cross-reaction acts on
transmission. So susceptible individuals are infected with serotype
i at rate λi ¼ β0ðIiþsIj;iÞ=N where β0 is the transmission rate,
0oso1 corresponds to cross-protection and s41 corresponds
to cross-enhancement. All infected individuals recover at rate γ.
Those that recover from a primary infection become susceptible to
secondary infection, those that recover from a secondary infection
become immune to all further infections. No additional mortality
is associated with any infection.
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Fig. 1. Flow diagrams showing (a) the conventional structure for two serotype SIR
models with cross-protection or cross-enhancement with intensity s acting on
transmission and (b) the modiﬁed structure incorporating partial cross-enhancement
with prevalence ρ and intensity χ and partial cross-protectionwith prevalence 1ρ and
intensity η. For clarity demographic turnover has been omitted from both diagrams.
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Our revised framework splits each of the secondary susceptible
compartments Si into two (Fig. 1b): those that are susceptible to
secondary infection with immune cross-reaction enhancing trans-
mission SiE and those that are susceptible to secondary infection
with immune cross-reaction reducing transmission SiP. This split
carries through to the secondary infected compartments IPj;i and I
E
j;i.
We deﬁne ρ to be the prevalence of enhancement. After a primary
infection, a proportion ρ become susceptible to secondary infec-
tion with enhancement increasing their transmissibility when
infected. A proportion 1ρ become susceptible to secondary
infection with partial protection reducing their transmissibility.
Then individuals susceptible to primary or secondary infection
with serotype i are infected at rate λi ¼ β0ðIiþηIPj;iþχIEj;iÞ=N where
χ41 is the intensity of enhancement and 0rηr1 is the degree
of protection. This formulation means that, relative to the trans-
mission rate β0 of primary infections, the transmission rate of
secondary infections is increased by a factor χ in enhanced
individuals and decreased by a factor η in protected individuals.
The system is therefore given by
_S0 ¼ μðλ1þλ2þμÞS0;
_I1 ¼ λ1S0ðγþμÞI1;
_S
E
2 ¼ ργI1ðλ2þμÞSE2;
_S
P
2 ¼ ð1ρÞγI1ðλ2þμÞSP2;
_I
E
1;2 ¼ λ2SE2ðγþμÞIE1;2;
_I
P
1;2 ¼ λ2SP2ðγþμÞIP1;2;
⋮
_R ¼ γðIE2;1þ IP2;1þ IE1;2þ IP1;2ÞμR
with the omitted equations deﬁned in the obvious way. Parameter
deﬁnitions and values are given in Table 1.
The model splits the population into those prone/not prone to
enhanced secondary infection at the point of recovery from
primary infection. Alternatively, all individuals susceptible to
secondary infection with a given serotype could be considered
identical and the occurrence, or not, of enhancement determined
when an individual succumbs to a secondary infection. It is thought
that FCγ receptors are important for determining the occurrence of
DHF. The FCγRIIa receptor has been associated with severe disease
whereas the RR variant has been associated with subclinical
infection (Garciá et al., 2010; Loke et al., 2002). Polymorphisms at
some HLA loci may also be important determinants of DHF
susceptibility (Sierra et al., 2007; Mathew and Rothman, 2008).
So we split the population at the point of recovery because it
corresponds best to genetic predisposition to enhancement.
In the conventional model framework, the intensity of enhance-
ment s is often taken as a bifurcation parameter. For s less than 1,
there is a stable endemic equilibrium solution. As s increases above
1 a Hopf bifurcation soon occurs indicating a transition to oscillatory
solutions. Initially these solutions are periodic but when s is
increased further, period doubling quickly leads to chaos (Ferguson
et al., 1999a; Adams and Boots, 2006). The Hopf bifurcation divides
the parameter space into regions in which the system exhibits non-
oscillatory and oscillatory behaviours. The oscillatory behaviour has
been associated with observed epidemiological patterns. So, for our
modiﬁed model we are interested in using the equivalent Hopf
bifurcation to identify regions of the parameter space deﬁned by ρ
(enhancement prevalence), χ (enhancement intensity) and η (degree
of protection if not enhanced) in which the system is expected
to oscillate. Recall that if ρ¼ 1 everyone is prone to enhanced
secondary infections, η is irrelevant and the system is equivalent to
the conventional model with χ ¼s. If ρ¼ 0 no-one is prone to
enhanced secondary infection, χ is irrelevant and the system is
equivalent to the conventional model with η¼s.
Fig. 2a shows, for different enhancement intensities χ, how the
system behaviour changes as the enhancement prevalence ρ
decreases from 1 to 0. If χ ¼ 2 the endemic equilibrium is stable
for ρ¼ 1, and remains so as ρ decreases. If the enhancement
intensity is higher, χ ¼ 3 or χ ¼ 5 the system exhibits chaotic
oscillations for ρ¼ 1. As ρ decreases, chaos is replaced with
periodic oscillations and then the endemic solution becomes stable
at a Hopf bifurcation. More intense enhancement results in chaotic
oscillations persisting at lower enhancement prevalences. System
behaviour depends on ρ and χ in a qualitatively similar way
regardless of the degree of cross-protection in the population not
prone to enhanced infection (Fig. 2a shows η¼ 1, Figure S1 in the
Supplementary Information shows η¼ 0:5 and 0). Quantitatively, if
cross-protection is weaker (higher η), for any given enhancement
intensity χ, oscillations persist at lower enhancement prevalence ρ.
Fig. 2b shows the location of the Hopf bifurcation in the
enhancement prevalence–intensity (ρ–χ) parameter space. The sys-
tem is oscillatory to the left of the lines, non-oscillatory to the right.
Note the log scale on the vertical axis. As enhancement prevalence
(ρ) decreases the enhancement intensity required for the system to
become oscillatory increases very rapidly. The boundary between the
oscillatory and non-oscillatory regions is qualitatively similar regard-
less of the degree of cross-protection in the population not prone to
enhancement. Quantitatively, if cross-protection is stronger (lower
η), oscillations require higher enhancement prevalences (ρ) and/or
intensities (χ). In all cases, if enhancement prevalence is less than
20%, the system is non-oscillatory unless the enhancement increases
transmission by at least an order of magnitude.
Our modiﬁed framework only shows persistent oscillations if the
proportion of the population that is prone to enhanced secondary
infection is large or the transmission increase in those prone to
enhanced infections is very high. It is, however, reasonable to ask if
the conventional framework provides an acceptable approximation
to our new framework if the ‘average’ cross-reaction in the popula-
tion is the same in both models. To investigate this we deﬁne the
expected cross-reaction χ ¼ ρχþð1ρÞη. If η is ﬁxed then χ can be
determined as a function of ρ such that the expected cross-
enhancement is the same for all enhancement prevalences (see
Figure S2a in the Supplementary Information). The value of η was
ﬁxed at 11 values between 0 and 1. For each value of η, the location
of the Hopf bifurcation in the enhancement prevalence–intensity
(ρ–χ) parameter space was found, and the corresponding expected
Table 1
Parameter deﬁnitions and values for models considered in this study. Where possible
these have been taken from the corresponding conventional models (Ferguson et al.,
1999a; Adams et al., 2006; Wearing and Rohani, 2006). All rates are per year.
Parameter Deﬁnition Model
1
Model
2
Model
3
N Total population size 1 1 106
μ Birth and death rate 0.02 0.017 0.02
γ Recovery rate 99.98 52 60.8
ρ Prevalence of enhancement 0–1 0–1 0–1
χ Intensity of enhancement 1–1 1–1 1–1
η Degree of cross-protection 0–1 0–1 0–1
β0 Baseline transmission rate 200 120 70
δ1 Baseline transmission seasonality
amplitude
– 0.1 –
Φ Random variation in seasonality
amplitude
– 1–1.25 –
sH Host infection activation rate – – 73
δ2 Temporary cross-protection loss rate – – 2–365
sV Vector infection activation rate – – 36.5
a Vector birth rate seasonality amplitude – – 0.05
μV Vector death rate/baseline birth rate – – 26.1
k Average number female vectors per
host
– – 2
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cross-enhancement calculated. In all cases the expected enhance-
ment at the bifurcation point was, strikingly, identical.
3. Model 2: Two serotype SIR model with stochastic
seasonality and partial cross-enhancement
Here we consider the implications of our new framework for
cross-enhancement in the context of a seasonally forced model
with stochastic variation in the forcing amplitude (Adams et al.,
2006). The compartment system is similar to model 1, but
enhancement and protection increase or decrease susceptibility
rather than transmission, and co-infection is permitted. The co-
infected state requires that the population is split into groups
susceptible to enhanced and protected secondary infections at the
primary infection stage (Ii), but otherwise the basic model struc-
ture is the same. The key parameters ρ, χ and η are deﬁned as
before. The main difference between model 2 and model 1 is the
transmission rate. In model 2, the transmission rate varies sea-
sonally βðtÞ ¼ β0ð1þδ1Φ sin ð2πtÞÞ, reﬂecting seasonal variation in
vector density and competence, where the amplitude of this
seasonal variation δ1Φ is subject to biannual random variation.
Therefore the model equations are given by
_S0 ¼ μðλ1þλ2þμÞS0;
_I
E
1 ¼ ρλ1S0χλ2IE1ðγþμÞIE1;
_I
P
1 ¼ ð1ρÞλ1S0ηλ2IP1ðγþμÞIP1;
_I ¼ χðλ1IE2þλ2IE1Þþηðλ1IP2þλ2IP1Þð2γþμÞI;
_S
E
2 ¼ γIE1ðχλ2þμÞSE2;
_S
P
2 ¼ γIP1ðηλ2þμÞSP2;
_I1;2 ¼ χλ2SE2þηλ2SP2þγIðγþμÞI1;2;
⋮
_R ¼ γðI2;1þ I1;2ÞμR
with
λ1 ¼
βðtÞðIE1þ IP1þ Iþ I2;1Þ
N
and Φ re-assigned with a uniformly distributed random number
between 1 and 1.25 whenever t is such that sin ð2πtÞ ¼ 0. The
omitted equations are deﬁned in the obvious way. Parameter
deﬁnitions and values are given in Table 1.
Setting ρ¼ 0 regains the conventional model with the para-
meter η determining the cross-reactive state of all secondary
susceptible individuals. As usual, values 0rηr1 correspond to
cross-protection. Allowing η41 would correspond to cross-
enhancement. The stochastic variation in the seasonal forcing
prevents the system from converging to a regular periodic solution
in any region of parameter space. Instead the conventional system
shows three generic behaviours, depending on the value of η.
In addition to the seasonal oscillation directly associated with the
forcing, serotype prevalence may show underlying oscillations
with a multi-annual period and serotypes in phase, oscillations
with a longer multi-annual period and serotypes out of phase, or
chaotic oscillations characterised by very large, infrequent
epidemics and no discernible phase structure (Adams et al.,
2006), Fig. 3c. Empirical data have been associated with an out
of phase serotype pattern. In the conventional model framework,
out of phase patterns occur when η is in a narrow band around 0.4,
representing a moderate degree of cross-protection. Other values
of η give in phase patterns or, if η is allowed to be sufﬁciently
greater than 1, chaos.
For our modiﬁed model we are interested in how enhancement
prevalence ρ and intensity χ affect the occurrence of out of phase
serotype patterns. When ρ¼ 0 out of phase oscillations occur for
η around 0.4 (Fig. 3a,b). Increasing ρ introduces enhancement with
intensity χ and reduces the prevalence of cross-protection. Conse-
quently the region of the η parameter space for which out of phase
patterns occur shifts toward zero. As ρ increases further the out of
phase patterns disappear altogether, and chaotic patterns begin to
appear for η close to 1. For a modest enhancement intensity χ ¼ 2 the
out of phase patterns are no longer evident when ρ¼ 0:3. These
changes are accelerated by higher enhancement intensities χ (Sup-
plementary Information Figure S3). As before, we can also consider
models with the same expected cross-reaction but different enhance-
ment prevalences. For this model, χwas ﬁxed and η was determined
as a function of ρ to obtain a constant expected cross-protection
(ηr1). For some values of ρ the required value of η was negative
and so that expected cross-reaction was unattainable (see Figure S2b
in the Supplementary Information). For both χ values tested
(χ ¼ 2; χ ¼ 5), out of phase oscillations always occur when the
expected cross-protection is around 0.4, regardless of the enhance-
ment prevalence (see Supplementary Information Figure S2c).
4. Model 3: Two serotype SIR model with temporary
cross-protection and partial cross-enhancement
Here we consider the implications of our new framework for
cross-enhancement in the context of a deterministic seasonally
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forced model with an explicit vector population and, in the host, a
period of latency and a period of temporary complete cross-
protection following a primary infection (Wearing and Rohani,
2006). The host part of the model can be formulated with
compartments corresponding to the states susceptible to both
serotypes (S0), latent primary infection with serotype i (Ei), active
primary infection with serotype i (Ii), temporary cross-protection
against serotype i (Ci), susceptible to secondary infection with
serotype i (Si), latent secondary infection with serotype i (Ej;i),
active secondary infection with serotype i (Ij;i) and immune to
both serotypes (R). Our new framework for modelling enhance-
ment splits the secondary susceptible compartment Si into SiE and
Si
P. The key parameter is the duration of temporary complete cross-
protection 1=δ2. The model equations are therefore given by
_S0 ¼NμðλV1þλV2þμÞ
S0
N
;
_E1 ¼ λV1
S0
N
ðsþμÞE1;
_I1 ¼sE1ðγþμÞI1;
_C1 ¼ γI1ðδ2þμÞC1;
_S
E
2 ¼ ρδ2C1χλV2
SE2
N
μSE2;
_S
P
2 ¼ ð1ρÞδ2C1ηλV2
SP2
N
μSP2;
⋮
_R ¼ γðIP2;1þ IE2;1þ IP1;2þ IE1;2ÞμR;
_V S1 ¼ kNbðtÞμVðλH1þμV ÞVS1;
_ϵV1 ¼ λH1VS1ðsVþμV ÞϵV1;
_λV1 ¼ β0sVϵV1μVλV1;
with
λH1 ¼
β0ðI1þ IE2;1þ IP2;1Þ
N
;
bðtÞ ¼ 1a cos ð2πtÞ
and the omitted equations deﬁned in the obvious way. The state
variables for the vector population overlap. VS1, VS2 are the
susceptible populations, ϵV1, ϵV2 are the forces of latency, λV1,
λV2 are the forces of infection, and b(t) is the seasonally varying
birth rate. Parameter deﬁnitions and values are given in Table 1.
In the conventional model framework the duration of temporary
cross-protection (1=δ2) and the intensity of enhancement (χ)
determine the behaviour of the system. When cross-protection is
brief (1=δ2 small) and enhancement intensity is low (χ small) the
system exhibits annual oscillations (Fig. 4a). Increasing the enhance-
ment intensity χ sufﬁciently leads to ‘enhancement-induced’ multi-
annual oscillations. Alternatively, increasing the duration of cross-
protection ð1=δ2Þ sufﬁciently leads to ‘immunity-induced’ multi-
annual oscillations. If the duration of cross-protection is such that
immunity-induced oscillations occur, increasing the enhancement
intensity decreases their period. Empirical data have been associated
with oscillations of period around 3 in the aggregated time series for
all serotypes. In the conventional model, aggregate oscillations with
periods between 2 and 5 occur for a wide range of cross-immunity
durations and enhancement intensities (Supplementary Information
Figure S5a), although dynamics of each serotype may show oscilla-
tions with periods from 2 to 10 (Wearing and Rohani, 2006).
For our modiﬁed model we are interested in how enhancement
prevalence (ρ) and enhancement intensity χ interact with the
duration of temporary cross-protection to determine the period of
oscillations. We ﬁrst consider η¼ 1, so individuals that are not
prone to enhanced secondary infection do not have any protection
against secondary infection either. Setting ρ¼ 1 regains the
original model. As enhancement prevalence ρ is reduced, the
enhancement intensity required for enhancement induced multi-
annual oscillations increases, beyond the range we considered
(Fig. 4b). The duration of cross-protection required for immunity-
induced oscillations increases slightly as enhancement prevalence
decreases. This effect is more pronounced when enhancement
intensity is higher. There is little change in the period of
immunity-induced oscillations, when they occur, either for each
serotype individually (Fig. 4c) or the aggregate of both serotypes
(Supplementary Information Figure S5). We now consider η¼ 0, so
individuals that are not prone to enhanced secondary infection
have complete protection against secondary infection. In this case,
as enhancement prevalence ρ is reduced, the duration of cross-
protection required for immunity-induced oscillations increases
markedly (Fig. 4d–f). This effect is more pronounced when
enhancement intensity is lower. The period of immunity-induced
oscillations, when they occur, is generally higher and there is
a sharper transition from period 1 oscillations to high period
oscillations. This pattern is seen in the time series for the
prevalence of each serotype individually, and when aggregated
(Supplementary Information Figure S5). It is interesting that the
onset of immunity-induced oscillations requires longer durations
of temporary cross-protection at high enhancement intensities
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prevalences of serotype 1 and serotype 2 at lag 0. Lower values indicate more out of phase patterns and (c) examples of the three types of behaviour typically displayed by
the system: large, chaotic oscillations; out of phase oscillations with period around 10; in phase oscillations with period around 6. The initial condition was the serotype
1 only endemic equilibrium of the non-seasonal model. The system was solved with stochastic perturbation for a random time of between 0.5 and 1.5 years, then serotype
2 was introduced at very low prevalence and the system solved for 5000 years before output time series were generated. All ﬁgures are derived from 100 year time series of
the total prevalence of each serotype (IEi þ IPi þ Iþ Ij;i), smoothed using a moving average method to remove seasonality. The dominant period was determined from the power
spectrum. Each point in (a) and (b) is the average of 20 independent model realisations. Enhancement intensity χ ¼ 2. Other parameters as in Table 1.
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when permanent cross-protection (η) is weak, but at low enhance-
ment intensities when permanent cross-protection is strong. The
change occurs between η¼0.2 and 0.1 (Supplementary Informa-
tion Figure S4). Together, these results show that immunity-driven
multi-annual oscillations are a complex product of the duration of
temporary cross-protection, enhancement prevalence, enhance-
ment intensity and the degree of permanent cross-protection.
As with the previous models, the expected cross-enhancement can
be held constant as ρ varies by ﬁxing η and determining χ as a
function of ρ. If the duration of temporary cross-protection is ﬁxed
at 1=δ2 ¼ 15 weeks, there is no permanent cross-protection (η¼ 1)
and the expected cross-enhancement is close to 1, the system
shows similar oscillations regardless of the prevalence of enhance-
ment (See Supplementary Information Figure S2d). As the
expected cross-enhancement increases away from 1, changing
the enhancement prevalence leads to some small variation in
the period of oscillations. This effect is more pronounced when the
duration of temporary cross-protection is longer.
5. Discussion and conclusions
It is conventional to model immune cross-enhancement with a
two serotype SIR model in which all individuals that recover from a
primary infection become susceptible to enhanced secondary infec-
tion. In this study we noted data that suggest only a small proportion
of primary infected individuals become susceptible to enhanced
secondary infection, and modiﬁed three variants of the conventional
model to reﬂect this observation. In the conventional enhancement
framework, basic two serotype models (e.g. Ferguson et al., 1999a;
Adams and Boots, 2006) require just a small enhancement of
susceptibility or transmission to show persistent oscillatory dynamics.
In our modiﬁed partial cross-enhancement framework, for all
enhancement prevalences the basic two serotype model shows
persistent oscillatory behaviour at the same threshold of the average
cross-reaction in the whole population. However, decomposing the
expected enhancement into weighted components of protection and
enhancement shows that oscillations only occur if the proportion of
the population that is prone to enhanced secondary infection is large
or the transmission increase in those prone to enhanced infections is
very high. These results weaken the hypothesis that ADE is driving the
oscillatory dynamics of dengue. Alternative hypotheses include sto-
chastic seasonality (Adams et al., 2006) and a period of temporary
complete cross-immunity following a primary infection (Wearing
and Rohani, 2006). We rendered the models used to support these
hypotheses in our partial cross-enhancement framework and
re-evaluated their behaviour.
In the conventional enhancement framework, a model in which
stochastic seasonality drives multi-annual epidemic oscillations
(Adams et al., 2006) predicts that two serotypes will have regular
out of phase epidemic oscillations only when all secondary susceptible
individuals have moderate partial protection against infection.
Enhancement leads to highly irregular oscillations. In our modiﬁed
partial cross-enhancement framework, for all enhancement preva-
lences, these out of phase oscillations occur over the same range of
values for the average cross-protection in the population. Considering
the components of the expected cross-protection shows that, as the
prevalence of enhancement increases, out of phase oscillations
require stronger partial protection against secondary infection in
the population group not prone to enhancement. If there is a
moderate to high prevalence of enhancement out of phase
epidemic oscillations do not occur. So, our partial cross-
enhancement framework neither supports nor refutes the
hypothesis that stochastic seasonality is driving the oscillatory
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Fig. 4. Dominant period of oscillations in serotype 1 prevalence depending on duration of temporary cross-protection (1=δ2), enhancement intensity χ and enhancement
prevalence ρ. (a–c) Individuals not prone to enhancement are not protected against secondary infection, η¼ 1. (d–f) Individuals not prone to enhancement are completely
protected against secondary infection, η¼ 0. Note that when ρ¼ 1, the parameter η is redundant. In all cases the system was solved for 2500 years from an initial condition
with 29% of the population fully susceptible and 71% fully recovered when infection is introduced. Then the dominant period was determined from the power spectrum of a
500 year time series of the total prevalence of serotype 1 (I1þ IE2;1þ IP2;1). Parameters as given in Table 1.
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dynamics of dengue. It does, however, indicate that partial cross-
enhancement may be interacting with a seasonal driver to
inﬂuence the period and phase structure of the epidemic
oscillations.
In the conventional enhancement framework, a sufﬁciently long
period of temporary but complete cross-protection between ser-
otypes can drive multi-annual epidemic oscillations. The long-term
immune interaction, whether partial cross-protection or cross-
enhancement, inﬂuences the period of these oscillations (Wearing
and Rohani, 2006; Aguiar et al., 2011). In our modiﬁed partial cross-
enhancement framework, temporary complete cross-protection still
drives multi-annual oscillations. The period of these oscillations
only shows a mild response to the enhancement prevalence if the
average cross-reaction in the population does not change. However,
considering the components of the expected cross-reaction shows
that the prevalence of enhancement in the secondary susceptible
population and the degree of long-term partial cross-protection in
the remainder of that population interact to have a strong impact on
the duration of temporary cross-protection required for multi-
annual oscillations. These factors also affect the period of such
oscillations. So, our partial cross-enhancement framework neither
supports nor refutes the hypothesis that temporary cross-protection
is driving the oscillatory dynamics of dengue. It does, however,
indicate that there is a complex interaction between this driver and
the long-term immunological interactions which may be inﬂuen-
cing the epidemic oscillations.
In this study we have argued that the conventional framework
for modelling cross-enhancement between dengue serotypes
should be modiﬁed to account for the observation that only a small
proportion of the secondary susceptible population is actually prone
to enhancement. We have shown that models modiﬁed in this way
generally produce similar dynamical behaviour to conventional
models if they are parameterised to have the same average cross-
reaction over the whole population. However, breaking down the
average cross-reaction into its constituent parts reveals that appar-
ently reasonable values for the average cross-reaction may be
underpinned by parameterisations that are difﬁcult to justify. Most
notably, when the enhancement prevalence is low, the individual
enhancement intensity needs to be very high to achieve enhance-
ment on average over the whole population. Consequently, insights
from models with conventional enhancement frameworks should
be re-evaluated. Future modelling studies that include dengue
serotype cross-reaction, and particularly those involving estimation
of immune cross-reaction parameters, should employ a partial
cross-enhancement framework.
Acknowledgements
This research was supported by an EPSRC postgraduate stu-
dentship awarded to HW.
Appendix A. Supplementary Information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.jtbi.2014.02.016.
References
Adams, B., Boots, M., 2006. Modelling the relationship between antibody-
dependent enhancement and immunological distance with application to
dengue. J. Theor. Biol. 242 (2), 337–346.
Adams, B., Holmes, E.C., Zhang, C., Mammen, M.P., Nimmannitya, S., Kalayanarooj, S.,
Boots, M., 2006. Cross-protective immunity can account for the alternating
epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc. Natl.
Acad. Sci, 103 (38), 14234–14239.
Aguiar, M., Kooi, B., Stollenwerk, N., 2008. Epidemiology of dengue fever: a model
with temporary cross-immunity and possible secondary infection shows
bifurcations and chaotic behaviour in wide parameter regions. Math. Model.
Nat. Phenom. 3 (4), 48–70.
Aguiar, M., Ballesteros, S., Kooi, B.W., Stollenwerk, N., 2011. The role of seasonality
and import in a minimalistic multi-strain dengue model capturing differences
between primary and secondary infections: complex dynamics and its implica-
tions for data analysis. J. Theor. Biol. 289, 181–196.
Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., Drake, J.M.,
Brownstein, J.S., Hoen, A.G., Sankoh, O., Myers, M.F., George, D.B., Jaenisch, T.,
Wint, G.R.W, Simmons, C.P., Scott, T.W., Farrar, J.F., Hay, S.I., 2013. The global
distribution and burden of dengue. Nature 496 (7446), 504–507.
Bianco, S., Shaw, L.B., Schwartz, I.B., 2009. Epidemics with multistrain interactions:
the interplay between cross immunity and antibody-dependent enhancement.
CHAOS 19 043123–1–043123–9.
Billings, L., Schwartz, I.B., Shaw, L.B., McCrary, M., Burke, D.S., Cummings, D.A.T.,
2007. Instabilities in multiserotype disease models with antibody-dependent
enhancement. J. Theor. Biol. 246, 18–27.
Ferguson, N., Andreasen, V., 2002. The inﬂuence of different forms of cross-protective
immunity on the population dynamics of antigenetically diverse populations. In:
Castillo-Chavez, C., Blower, S., Kirschner, D., van den Driessche, P., Yakubu, A.
(Eds.), Mathematical Approaches for Emerging and Reemerging Infectious
Diseases: Models, Methods and Theory. IMA Volumes Mathematics and its
Applications, vol. 126. Kluwer Academic Publishers, New York, pp. 157–169.
Ferguson, N., Anderson, R., Gupta, S., 1999a. The effect of antibody-dependent
enhancement on the transmission dynamics and persistence of multiple-strain
pathogens. Proc. Natl. Acad. Sci. 96, 790–794.
Ferguson, N., Donnelly, C.A., Anderson, R., 1999b. Transmission dynamics and
epidemiology of dengue: insights from age-stratiﬁed sero-prevalence surveys.
Philos. Trans. R. Soc. B Biol. Sci. 354 (1384), 757–768.
Garciá, G., Sierra, B., Pérez, A.B., Aguirre, E., Rosado, I., Gonzalez, N., Izquierdo, A.,
Pupo, M., Díaz, D.R.D., Sánchez, L., Marcheco, B., Hirayama, K., Guzmán, M.G.,
2010. Asymptomatic dengue infection in a Cuban population conﬁrms the
protective role of the RR variant of the Fcγ RIIa polymorphism. Am. J. Trop. Med.
Hyg. 82 (6), 1153–1156.
Gubler, D.J., Kuno, G., 2004. Dengue and Dengue Hemorrhagic Fever. CABI Publish-
ing, Oxon, United Kingdom
Guzmán, M.G., Kouri, G., 2002. Dengue: an update. Lancet Infect. Dis. 2 (1), 33–42.
Guzman, M.G., Vazquez, S., 2010. The complexity of antibody-dependent enhance-
ment of dengue virus infection. Viruses 2, 2649–2662.
Guzmán, M.G., Kouri, G., Bravo, J., Valdes, L., Vazquez, S., Halstead, S.B., 2002. Effect of
age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 6, 118–124.
Loke, H., Bethell, D., Phuong, C.X.T., Day, N., White, N., Farrar, J., Hill, A., 2002.
Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an
association with variation in the vitamin D receptor and FCγ receptor IIA
genes. Am. J. Trop. Med. Hyg. 67 (1), 102–106.
Mathew, A., Rothman, A.L., 2008. Understanding the contribution of cellular
immunity to dengue disease pathogenesis. Immunol. Rev. 225, 300–313.
Nisalak, A., Endy, T.P., Nimmannitya, S., Kalayanarooj, S., Thisayakorn, U., Scott, R.M.,
Burke, D.S., Hoke, C.H., Innis, B.L., Vaughn, D.W., 2003. Serotype-speciﬁc dengue
virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999.
Am. J. Trop. Med. Hyg. 68 (2), 191–202.
Recker, M., Blyuss, K.B., Simmons, C.P., Hien, T.T., Wills, B., Farrar, J., Gupta, S., 2009.
Immunological serotype interactions and their effect on the epidemiological
pattern of dengue. Proc. R. Soc. B Biol. Sci. 276 (1667), 2541–2548.
Reich, N.G., Shrestha, S., King, A.A., Rohani, P., Lessler, J., Kalayanarooj, S., Yoon, I.-K.,
Gibbons, R.V., Burke, D.S., Cummings, D.A.T., 2013. Interactions between
serotypes of dengue highlight epidemiological impact of cross-immunity. J. R.
Soc. Interface 10 (86), 20130414.
Sabchareon, A., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba,
S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Margolis, H.S., Letson, W.G., 2012.
Dengue infection in children in Ratchaburi, Thailand: a cohort study. I.
Epidemiology of symptomatic acute dengue infection in children, 2006–2009.
PLoS Negl. Trop. Dis. 6 (7), e1732, http://dx.doi.org/10.1371/journal.
pntd.0001732.
Sabin, A.B., 1952. Research on dengue during world war II. Am. J. Trop. Med. Hyg. 1
(1), 30–50.
Sangkawibha, N., Rojanasuphot, S., Ahandrik, S., Viriyapongse, S., Jatanasen, S.,
Salitul, V., Phanthumachinda, B., Halstead, S.B., 1984. Risk factors in dengue
shock syndrome: a prospective epidemiological study in Rayong, Thailand. Am.
J. Epidemiol. 120 (5), 653–669.
Schwartz, I.B., Shaw, L.B., Cummings, D.A.T., Billings, L., McCrary, M., Burke, D.S., 2005.
Chaotic desynchronization of multistrain diseases. Phys. Rev. E 72, 066201.
Sierra, B., Alegre, R., Pérez, A.B., García, G., Sturn-Ramirez, K., Obasanjo, O., Aguirre,
E., Alvarez, M., Rodriguez-Roche, R., Valdés, L., Kanki, P., Guzmán, M.G., 2007.
HLA–A, –B, –C, and –DRB1 allele frequencies in Cuban individuals with
antecedents of dengue 2 disease: advantages of the Cuban population for
HLA studies of dengue virus infection. Hum. Immunol. 68, 531–540.
Wearing, H.J., Rohani, P., 2006. Ecological and immunological determinants of
dengue epidemics. Proc. Natl. Acad. Sci. 103 (31), 11802–11807.
Wikramaratna, P.S., Simmons, C.P., Gupta, S., Recker, M., 2010. The effects of tertiary
and quaternary infections on the epidemiology of dengue. PLOS One 5 (8),
e12347.
World Health Organization, 2012. Dengue and severe dengue. 〈http://www.who.
int/mediacentre/factsheets/fs117/en/〉.
H. Woodall, B. Adams / Journal of Theoretical Biology 351 (2014) 67–73 73
